AML, in general, is much more common in adults than children. The average lifetime risk of AML in the US is approximately 0.5%, translating to approximately 19,520 new cases in 2018.
According to the Merck Manual, some of the more common cytogenetic abnormalities of AML include:
- AML with APL-RARA (t15;17)(q24.1). This is a type of promyelocytic leukemia (FAB category M3). Approximately 13% of AML is this subtype.
- AML with inv(16)(p13.1;q22) or t(16;16)/CBFB-MY11. Approximately 5% of AML is this subtype.
- AML with t(8;21)/(q22;q22)/RUNX1-RUNX1T1. This example was shown on a previous page and occurs in approximately 7% of AML cases.
Prognosis related to these and several other subtypes will be discussed in subsequent pages.